The 36-month beta value for SANA is at 1.46. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SANA is 120.52M, and currently, shorts hold a 21.58% of that float. The average trading volume for SANA on July 25, 2024 was 1.94M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SANA) stock’s latest price update
The stock of Sana Biotechnology Inc (NASDAQ: SANA) has decreased by -2.70 when compared to last closing price of 6.29.Despite this, the company has seen a loss of -4.08% in its stock price over the last five trading days. investorplace.com reported 2024-05-08 that Sana Biotechnology (NASDAQ: SANA ) just reported results for the first quarter of 2024. Sana Biotechnology reported earnings per share of -32 cents.
SANA’s Market Performance
SANA’s stock has fallen by -4.08% in the past week, with a monthly rise of 10.47% and a quarterly drop of -24.35%. The volatility ratio for the week is 7.61% while the volatility levels for the last 30 days are 7.03% for Sana Biotechnology Inc The simple moving average for the last 20 days is 7.85% for SANA’s stock, with a simple moving average of -3.78% for the last 200 days.
Analysts’ Opinion of SANA
Many brokerage firms have already submitted their reports for SANA stocks, with Rodman & Renshaw repeating the rating for SANA by listing it as a “Buy.” The predicted price for SANA in the upcoming period, according to Rodman & Renshaw is $16 based on the research report published on June 26, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see SANA reach a price target of $12. The rating they have provided for SANA stocks is “Buy” according to the report published on January 16th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to SANA, setting the target price at $9 in the report published on September 25th of the previous year.
SANA Trading at -8.73% from the 50-Day Moving Average
After a stumble in the market that brought SANA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.00% of loss for the given period.
Volatility was left at 7.03%, however, over the last 30 days, the volatility rate increased by 7.61%, as shares surge +12.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.05% lower at present.
During the last 5 trading sessions, SANA fell by -4.08%, which changed the moving average for the period of 200-days by +62.33% in comparison to the 20-day moving average, which settled at $5.71. In addition, Sana Biotechnology Inc saw 50.00% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SANA starting from Yang Patrick Y, who sale 25,000 shares at the price of $9.45 back on Mar 08 ’24. After this action, Yang Patrick Y now owns 149,250 shares of Sana Biotechnology Inc, valued at $236,300 using the latest closing price.
NELSEN ROBERT, the Director of Sana Biotechnology Inc, purchase 1,818,181 shares at $5.50 during a trade that took place back on Feb 08 ’24, which means that NELSEN ROBERT is holding 12,446,022 shares at $9,999,996 based on the most recent closing price.
Stock Fundamentals for SANA
The total capital return value is set at -0.48. Equity return is now at value -76.82, with -43.21 for asset returns.
Based on Sana Biotechnology Inc (SANA), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -2.26.
Currently, EBITDA for the company is -294.94 million with net debt to EBITDA at 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.07.
Conclusion
In conclusion, Sana Biotechnology Inc (SANA) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
